Prophylactic Bilateral Salpingectomy and Laparoscopic Myomectomy

Sponsor
University Magna Graecia (Other)
Overall Status
Unknown status
CT.gov ID
NCT01929148
Collaborator
(none)
154
1
2
40
3.8

Study Details

Study Description

Brief Summary

We already demonstrated that the addiction of PBS to Total Laparoscopic Hysterectomy (TLH) has no negative effects in term of ovarian function, evaluated by anti-Müllerian hormone (AMH), Follicle Stimulating Hormone (FSH), Antral Follicle Count (AFC), mean ovarian diameters and Peak Systolic Velocity (PSV). In addition, in our experience, no negative surgical outcomes (in terms of operative time, intraoperative blood loss, postoperative hospital stay, postoperative return to normal activity and complication rate) are related to PBS step in TLH.

Although the good statistical reliability of our retrospective data, we want to prospectively confirm our results. Moreover we aim to refine PBS safety demonstration by collecting also 3D ultrasound parameters [AFC, ovarian volume (OV), Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI)]. Hormonal and ultrasonographic parameters may possibly be unified into a new diagnostic algorithm (already at an advanced stage of production in UMG Department) able to estimate the ovarian function both in term of reproductive ability that in term of distance from menopause.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Prophylactic bilateral salpingectomy
  • Procedure: Laparoscopic myomectomy without PBS
N/A

Detailed Description

We will enroll the first 77 patients who will agree to implement PBS to laparoscopic myomectomy (LM) (study group), starting from September 1, 2013. Other 77 patients who will ask us to undergo LM without the addiction of PBS will constitute the control group. For each patient, ovarian reserve modification before and after surgery will be recorded as the primary outcome. Specifically, one month before and three months after laparoscopy, on day 1 to 4 of menstrual cycles serum AMH, FSH and E2 will be evaluated and a transvaginal ultrasound examination (Voluson E8 Expert or Voluson-i - GE Healthcare Ultrasound) to assess AFC, OV, VI, FI and VFI, will be carried out by the same experienced ultrasonographist responsible for the ambulatory of ovarian reserve in each Unit.

Ovarian reserve modification will be defined as the difference (expressed as Δ) between post-operative and pre-operative values of AMH, FSH, AFC, OV, VI, FI and VFI. For each surgical procedure, moreover, operative time, variation of hemoglobin level, postoperative hospital stay, postoperative return to normal activity and complication rate will be recorded as secondary outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
154 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Is Prophylactic Bilateral Salpingectomy Added to Laparoscopic Myomectomy as New Preventive Strategy for Ovarian Cancer a Safe Procedure?
Study Start Date :
Aug 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Laparoscopic myomectomy plus PBS

A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire

Procedure: Prophylactic bilateral salpingectomy
Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
Other Names:
  • PBS, bilateral salpingectomy
  • Active Comparator: Laparoscopic myomectomy without PBS

    A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed

    Procedure: Laparoscopic myomectomy without PBS
    Standard laparoscopic myomectomy without salpingectomy
    Other Names:
  • LM
  • Outcome Measures

    Primary Outcome Measures

    1. Ovarian reserve modification [three months after laparoscopy]

      Ovarian reserve modification will be defined as the difference (expressed as Δ) between post-operative and pre-operative values of anti-Müllerian hormone (AMH), Follicle Stimulating Hormone (FSH), Antral Follicle Count (AFC), Ovarian volume (OV), Vascularization Index (VI), Flow index (FI) and Vascularization Flow Index (VFI)

    Secondary Outcome Measures

    1. Surgical outcomes [one day to one month after laparoscopy]

      For each surgical procedure operative time, variation of hemoglobin level, postoperative hospital stay, postoperative return to normal activity and complication rate will be recorded as secondary outcomes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Indication to laparoscopic myomectomy

    • Accomplished reproductive desire

    Exclusion Criteria:
    • Age older than 50 years

    • family history of ovarian cancer, BRCA positive

    • basal FSH value of >20 IU/mL and/or E2 levels >60 pg/mL

    • presence of menopausal symptoms,irregular (cycle-to-cycle variation over 12 months >20 days orpresence of any breakthrough bleeding) menstrual cycles, hormonereplacement treatment and/or hormonal contraception for the last 3 months, history of previous uterine or ovarian surgeries, and imaging suggestive of ovarian cyst or tubal pathology at transvaginal ultrasound.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Magna Graecia University - Azienda Ospedaliera Pugliese Ciaccio Catanzaro CZ Italy 88100

    Sponsors and Collaborators

    • University Magna Graecia

    Investigators

    • Study Director: Fulvio Zullo, Md, PhD, Magna Graecia University of Catanzaro
    • Principal Investigator: Roberta Venturella, Magna Graecia University of Catanzaro

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fulvio Zullo, Full Professor, University Magna Graecia
    ClinicalTrials.gov Identifier:
    NCT01929148
    Other Study ID Numbers:
    • PBS_myomectomy
    First Posted:
    Aug 27, 2013
    Last Update Posted:
    Nov 18, 2016
    Last Verified:
    Nov 1, 2016
    Keywords provided by Fulvio Zullo, Full Professor, University Magna Graecia
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2016